Filing Flows › Jazz Pharmaceuticals (JAZZ) › How it makes money
How Jazz Pharmaceuticals (JAZZ) makes money
Jazz Pharmaceuticals (JAZZ) made $1.2B of revenue in the third quarter 2026 (Q3 2026), +9% from a year earlier. Sleep brought in $514M (41%); Xywav brought in $482M (39%); Rylaze/Enrylaze brought in $106M (9%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Sleep | $514M | 41.3% | — | +10% |
| Xywav | $482M | 38.7% | — | +10% |
| ↳ Epidiolex/Epidyolex | $295M | 23.7% | — | -2% |
| ↳ Modeyso | $61.1M | 4.9% | — | +455% |
| ↳ Defitelio/defibrotide | $60.7M | 4.9% | — | +17% |
| ↳ Vyxeos | $34.0M | 2.7% | — | -10% |
| ↳ Xyrem | $31.2M | 2.5% | — | -13% |
| Rylaze/Enrylaze | $106M | 8.5% | — | +6% |
| Zepzelca | $104M | 8.4% | — | +32% |
| High-sodium oxybate AG royalty revenue | $38.4M | 3.1% | — | -27% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $1.2B | 100.0% |
| Income tax | $24.5M | 2.0% |
| Operating cash flow | $506M | 40.6% |
| Free cash flow | $490M | 39.3% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $1.2B | +10% |
| Q2 2026 | $1.2B | +16% |
| Q1 2026 | $1.1B | +19% |
| Q4 2025 | $1.2B | +10% |
| Q3 2025 | $1.1B | +7% |
| Q2 2025 | $1.0B | +2% |
| Q1 2025 | $898M | -0.5% |
From Jazz Pharmaceuticals' 10-Q filed Nov 2, 2026 (on EDGAR).
Questions
How does Jazz Pharmaceuticals make money?
Jazz Pharmaceuticals (JAZZ) made $1.2B of revenue in the third quarter 2026 (Q3 2026), +9% from a year earlier. Sleep brought in $514M (41%); Xywav brought in $482M (39%); Rylaze/Enrylaze brought in $106M (9%).
What is Jazz Pharmaceuticals' biggest business?
Sleep: $514M in the third quarter 2026, 41% of revenue, +10% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.